Alkermes targets $310M-$340M adjusted EBITDA amid LYBALVI growth and orexin pipeline expansion

Disclosure: This website may contain affiliate links, which means I may earn a commission if you click on the link and make a purchase. I only recommend products or services that I personally use and believe will add value to my readers. Your support is appreciated!